General MedicationsORALGeneric
LIBRELEASE
CHLORDIAZEPOXIDE
Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview LIBRELEASE is listed in Drugs@FDA under application 017813 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CHLORDIAZEPOXIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 30MG Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 1983-09-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIBRELEASE is listed in Drugs@FDA under application 017813 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CHLORDIAZEPOXIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 30MG Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 1983-09-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.